EA202090236A1 - IMMUNOGENIC COMPOSITIONS OF SENECAVIRUS A AND WAYS WITH THEM - Google Patents

IMMUNOGENIC COMPOSITIONS OF SENECAVIRUS A AND WAYS WITH THEM

Info

Publication number
EA202090236A1
EA202090236A1 EA202090236A EA202090236A EA202090236A1 EA 202090236 A1 EA202090236 A1 EA 202090236A1 EA 202090236 A EA202090236 A EA 202090236A EA 202090236 A EA202090236 A EA 202090236A EA 202090236 A1 EA202090236 A1 EA 202090236A1
Authority
EA
Eurasian Patent Office
Prior art keywords
senecavirus
immunogenic compositions
ways
immunogenic
vaccines
Prior art date
Application number
EA202090236A
Other languages
Russian (ru)
Inventor
Арун В. Ийер
Эбби Рэй Паттерсон
Джозеф Гильберт Виктория
Эрик Мартин Вон
Луис Алехандро Эрнандес
Дженнифер Л. Инглиш
Original Assignee
Бёрингер Ингельхайм Энимал Хелс Ю-Эс-Эй Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Энимал Хелс Ю-Эс-Эй Инк. filed Critical Бёрингер Ингельхайм Энимал Хелс Ю-Эс-Эй Инк.
Priority claimed from PCT/US2018/041321 external-priority patent/WO2019014144A1/en
Publication of EA202090236A1 publication Critical patent/EA202090236A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/085—Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1009—Picornaviridae, e.g. hepatitis A virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24271—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Настоящее изобретение относится к иммуногенным композициям и вакцинам, убитого/инактивированного и/или рекомбинантного Senecavirus A, a также способам профилактики или лечения животных, нуждающихся в этом, такой иммуногенной композицией и вакциной.The present invention relates to immunogenic compositions and vaccines, killed / inactivated and / or recombinant Senecavirus A, as well as methods for the prevention or treatment of animals in need thereof, such an immunogenic composition and vaccine.

EA202090236A 2017-11-22 2018-07-09 IMMUNOGENIC COMPOSITIONS OF SENECAVIRUS A AND WAYS WITH THEM EA202090236A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762590209P 2017-11-22 2017-11-22
PCT/US2018/041321 WO2019014144A1 (en) 2017-07-12 2018-07-09 Senecavirus a immunogenic compositions and methods thereof

Publications (1)

Publication Number Publication Date
EA202090236A1 true EA202090236A1 (en) 2020-06-02

Family

ID=71138799

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090236A EA202090236A1 (en) 2017-11-22 2018-07-09 IMMUNOGENIC COMPOSITIONS OF SENECAVIRUS A AND WAYS WITH THEM

Country Status (1)

Country Link
EA (1) EA202090236A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117304276A (en) * 2023-11-30 2023-12-29 江门海关技术中心 Virus-like particles containing foot-and-mouth disease virus type O and Sein card virus nucleic acid

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117304276A (en) * 2023-11-30 2023-12-29 江门海关技术中心 Virus-like particles containing foot-and-mouth disease virus type O and Sein card virus nucleic acid
CN117304276B (en) * 2023-11-30 2024-04-12 江门海关技术中心 Virus-like particles containing foot-and-mouth disease virus type O and Sein card virus nucleic acid

Similar Documents

Publication Publication Date Title
PH12020500080A1 (en) Senecavirus a immunogenic compositions and methods thereof
MX2018014573A (en) Zika virus vaccine.
MX2018005569A (en) Vaccines against hepatitis b virus.
TW201613558A (en) Novel vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus
MX2017001406A (en) Flagellin-based agents and uses including effective vaccination.
BR112018013387A2 (en) recombinant vaccination vector, mva virus, vaccine or pharmaceutical composition and kit
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
EA201800148A1 (en) CHALLENGE VACCINE FOR CANCER TREATMENT
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
EA201790507A1 (en) METHODS AND COMPOSITIONS FOR STRENGTHENING IMMUNE RESPONSES
EA201391515A1 (en) INACTIVATED DENGE VIRUS VACCINE
EA201991041A1 (en) VACCINE AGAINST PORK PARVOVIRUS AND PIG REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS AND METHODS FOR ITS PRODUCTION
PH12017500304A1 (en) Vaccine compositions against dengue virus diseases
EA201690859A1 (en) PREVENTION OF INFECTIONS CAUSED BY STAPHYLOCOCCUS AUREUS, GLYOPROTEIN VACCINES SYNTHESIZED IN ESCHERICHIA COLI
MX2017002803A (en) Attenuated bovine coronavirus and related vaccines.
EA201990010A1 (en) INFECTIOUS Bronchitis Virus Vaccine
EA201991377A1 (en) COMPOSITIONS OF A UNIVERSAL VACCINE AGAINST INFLUENZA
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
EA201892003A1 (en) TREATMENT OF ATOPIC DERMATITIS DOGS
BR112018074910A2 (en) immunological composition, and method of inducing an immune response against equine influenza virus in a subject
MX2017012389A (en) Recombinant mumps virus jeryl lynn 2 based vaccine.
EA201891555A1 (en) VACUS VIRUS FROM REPRODUCTIVE AND RESPIRATORY SYNDROME OF PIGS
EA202090236A1 (en) IMMUNOGENIC COMPOSITIONS OF SENECAVIRUS A AND WAYS WITH THEM
EA201790771A1 (en) PHARMACEUTICAL COMPOSITIONS OF LONG-TERM ACTION FOR THE TREATMENT OF HEPATITIS C